Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2010 Results Thursday, February 4th, 10:00 a.m. EST

WALTHAM, Mass., Jan. 29 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, February 4th, 2010 at 10:00 a.m. EST, to report third quarter fiscal year 2010 financial results and to provide a quarterly update of the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at  If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (800) 510-9836 for domestic calls and (617) 614-3670 for international calls.  Participants must provide the following passcode: 51466310.  For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.  In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability.  Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.  Additional information may be requested from

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

SOURCE Repligen Corporation



SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Vancouver ... lancet that features Owen Mumford,s unique Comfort Zone Technology®. ... Unistik® Touch is a touch activated lancet that features ... Owen Mumford, a leading medical device manufacturer, today unveils ... available initially in the US before expanding out to ...
(Date:12/1/2015)... , Dec. 1, 2015 Today the Allen ... Seattle,s South Lake Union neighborhood, ... of Mercer Street and Westlake Avenue North, the 270,000 ... Allen Institute for Brain Science and the Allen Institute ... philanthropist and founder of the Allen Institute. "We started ...
(Date:12/1/2015)... CAMBRIDGE, Mass. , Dec. 1, 2015 ... and the McGovern Institute for Brain Research at MIT ... system that significantly cut down on "off-target" editing errors. ... issues in the use of genome editing. ... report that changing three of the approximately 1,400 amino ...
(Date:12/1/2015)... Dec. 1, 2015  Twist Bioscience, a company focused on ... , Ph.D., has been selected as one of Foreign ... fast-tracking the building blocks of life . Each year, ... whose contributions and work have changed lives and are shaping ... "It is an honor to be recognized among these incredible ...
Breaking Biology Technology:
(Date:12/1/2015)... , Dec. 1, 2015 Synaptics Incorporated (NASDAQ: ... solutions, today announced a new agreement with Nok ... real-world test and development environments that combine FIDO Certified ... partnership reduces the complexity of FIDO certification for Synaptics, ... Synaptics and OEMs to verify FIDO enabled devices in ...
(Date:11/30/2015)... Nov. 30, 2015  BIOCLAIM announced today that ... year,s Fierce Innovation Awards:  Healthcare Edition, an awards ... , FierceHealthcare , and ... finalist in the category of "Privacy and Cybersecurity." ... --> Photo - ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Capacitive Fingerprint Sensors - Technology and Patent ... --> --> Fingerprint ... especially in smartphones. The fingerprint sensor vendor Idex forecasts ... sensor units in mobile devices and of the fingerprint ...
Breaking Biology News(10 mins):